{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:57:04Z","timestamp":1790618224834,"version":"4.1.0"},"reference-count":51,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sarcopenia is a skeletal muscle disorder characterised by reduced muscle strength, low muscle mass and impaired physical performance. It is increasingly recognised among patients with chronic kidney disease (CKD) and is associated with adverse clinical outcomes. However, evidence on sarcopenia among CKD patients in Ethiopia remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the prevalence of sarcopenia and its associated factors among adult CKD patients attending a tertiary hospital in Northwest Ethiopia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A hospital-based cross-sectional study was conducted among adult CKD patients attending the renal clinic of Felege Hiwot Comprehensive Specialised Hospital from September to November 2022. All eligible patients during the study period were consecutively included. Sarcopenia was assessed using the European Working Group on Sarcopenia in Older People 2 criteria, incorporating measurements of muscle strength, muscle mass and physical performance. Sociodemographic, clinical, anthropometric and biochemical data were collected using structured tools and laboratory analysis. Multivariable logistic regression analysis was performed to identify factors associated with sarcopenia, with statistical significance set at p&lt;0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 120 consecutive CKD patients were included, containing 60 patients without end-stage renal disease (ESRD) and 60 patients with ESRD. Among CKD patients without ESRD, 5 (8.3%), 13 (21.7%), 26 (43.3%) and 16 (26.7%) were classified as CKD stages 1, 2, 3 and 4, respectively. The prevalence of sarcopenia was significantly higher among patients with ESRD than among those without ESRD (28.3% vs 10.0%, p=0.01). The distribution of sarcopenia stages also differed significantly between the two groups (p=0.02). In multivariable analysis, decreased high-density lipoprotein, elevated triacylglycerol, increased fasting blood glucose, hypertension and frailty were significantly associated with sarcopenia. Furthermore, overall sarcopenia revealed significant associations with creatinine (r=\u22120.291, p=0.001), estimated glomerular filtration rate (r=0.260, p=0.004), frailty (r=0.566, p&lt;0.001), malondialdehyde (r=\u22120.392, p&lt;0.001) and total antioxidant capacity (r=0.455, p&lt;0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sarcopenia was predominant among CKD patients and was more common among those with ESRD. It was correlated with metabolic abnormalities, inflammation, oxidative stress and frailty. The findings indicate the necessity of routine screening and integrated management strategies in CKD patients. However, further longitudinal multicentre studies are needed to better understand the burden and determinants of sarcopenia in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-123421","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:00Z","timestamp":1790614860000},"page":"e123421","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Sarcopenia among chronic kidney disease patients attending a renal clinic in Northwest Ethiopia: a cross-sectional study of prevalence, risk factors and clinical implications"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8565-0920","authenticated-orcid":false,"given":"Melaku Mekonnen","family":"Agidew","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, College of Health Sciences, Debre Tabor University, Debre Tabor, Amhara, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girma","family":"Derso","sequence":"additional","affiliation":[{"name":"Noncommunicable Disease Control, Amhara Regional Health Bureau, Bahir Dar, Amhara, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092810003120000_16.9.e123421.1","doi-asserted-by":"crossref","DOI":"10.34172\/jnp.2025.27617","article-title":"Comparative analysis of inflammatory and oxidative stress indicators in rat models of CKD induced by adenine versus folic acid; an experimental study","volume":"14","author":"Fadhel Khalif","year":"2025","journal-title":"J Nephropathol"},{"key":"2026092810003120000_16.9.e123421.2","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"The Lancet"},{"key":"2026092810003120000_16.9.e123421.3","doi-asserted-by":"crossref","first-page":"925","DOI":"10.23937\/2572-3286\/1510095","article-title":"Magnitude of Metabolic Syndrome and its Associated Factors among Patients with Chronic Kidney Disease: Laboratory-Based Cross-Sectional Study in Northwest Ethiopia","volume":"10","author":"Melaku Mekonnen","year":"2024","journal-title":"J Clin Nephrol Ren Care"},{"key":"2026092810003120000_16.9.e123421.4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.531"},{"key":"2026092810003120000_16.9.e123421.5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1159\/000536465","article-title":"Prevalence of Sarcopenia in Chronic Heart Failure and Modulating Role of Chronic Kidney Disease","volume":"70","author":"Formiga","year":"2024","journal-title":"Gerontology"},{"key":"2026092810003120000_16.9.e123421.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2025.1524459","article-title":"Impact of ageing on alanine aminotransferase levels and frailty in chronic kidney disease patients: laboratory-based cross-sectional study in Northwest Ethiopia","volume":"12","author":"Agidew","year":"2025","journal-title":"Front Med"},{"key":"2026092810003120000_16.9.e123421.7","unstructured":"Alih MI , Abdoulrahman K . Estimation of liver parameters and oxidative stress in chronic renal failure patients on hemodialysis in Erbil governorate. AIP Publ 2017;1\u20138."},{"key":"2026092810003120000_16.9.e123421.8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.23876\/j.krcp.20.163","article-title":"Implications of oxidative stress in chronic kidney disease: a review on current concepts and therapies","volume":"40","author":"Verma","year":"2021","journal-title":"Kidney Res Clin Pract"},{"key":"2026092810003120000_16.9.e123421.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0315344","article-title":"Relationship between oxidative balance indicators and Chronic Kidney Disease","volume":"20","author":"Chen","year":"2025","journal-title":"PLoS ONE"},{"key":"2026092810003120000_16.9.e123421.10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-021-00898-1","article-title":"Sarcopenia in Chronic Kidney Disease: A Scoping Review of Prevalence, Risk Factors, Association with Outcomes, and Treatment","volume":"110","author":"Chatzipetrou","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2026092810003120000_16.9.e123421.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-016-0220-9"},{"key":"2026092810003120000_16.9.e123421.12","first-page":"1","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"0","author":"Entoft","year":"2018","journal-title":"Age Aging"},{"key":"2026092810003120000_16.9.e123421.13","first-page":"328","article-title":"Correlations between sarcopenia and hypertensive target organ damage in a Turkish cohort","volume":"67","author":"Do\u011fan","year":"2012","journal-title":"Acta Clin Belg"},{"key":"2026092810003120000_16.9.e123421.14","first-page":"98","article-title":"Sarcopenia in chronic kidney disease","volume":"37","author":"VA","year":"2015","journal-title":"J Bras Nefrol"},{"key":"2026092810003120000_16.9.e123421.15","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00840-y"},{"key":"2026092810003120000_16.9.e123421.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00498-0"},{"key":"2026092810003120000_16.9.e123421.17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/jcsm.13425","article-title":"Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis","volume":"15","author":"Duarte","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026092810003120000_16.9.e123421.18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.851618"},{"key":"2026092810003120000_16.9.e123421.19","doi-asserted-by":"crossref","first-page":"641","DOI":"10.25259\/IJN_241_2024","article-title":"Prevalence and Predictors of Sarcopenia, Protein-Energy Wasting, and Sarcopenic Obesity in Patients with Chronic Kidney Disease","volume":"35","author":"Yogesh","year":"2025","journal-title":"Indian J Nephrol"},{"key":"2026092810003120000_16.9.e123421.20","doi-asserted-by":"crossref","unstructured":"Mballa Yene BV , Lee S-Y , Park K-S , et al . . CIA 2023;Volume 18:1021\u201335. 10.2147\/CIA.S407917","DOI":"10.2147\/CIA.S407917"},{"key":"2026092810003120000_16.9.e123421.21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3390\/medicina61030449","article-title":"Comprehensive Insights into Sarcopenia in Dialysis Patients: Mechanisms, Assessment, and Therapeutic Approaches","volume":"61","author":"Zicarelli","year":"2025","journal-title":"Medicina (B Aires)"},{"key":"2026092810003120000_16.9.e123421.22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4172\/2161-0959.1000313","article-title":"The Magnitude of Chronic Kidney Disease and its Risk Factors at Zewditu Memorial Hospital, Addis Ababa, Ethiopia","volume":"08","author":"Kore","year":"2018","journal-title":"J Nephrol Ther"},{"key":"2026092810003120000_16.9.e123421.23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cgh.2011.10.014","article-title":"Serum levels of alanine aminotransferase decrease with age in longitudinal analysis","volume":"10","author":"Dong","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026092810003120000_16.9.e123421.24","unstructured":"WHO: WHO Steps Surveillance Manual . WHO STEPwise approach to surveillance \u2013 Q-by-Q Guide v.3.2. 2017."},{"key":"2026092810003120000_16.9.e123421.25","first-page":"499","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"J Am Hear Assoc"},{"key":"2026092810003120000_16.9.e123421.26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/VHRM.S297403","article-title":"Prevalence of Hypertension and Associated Factors Among Adults in Debre Berhan Town, North Shoa Zone, Ethiopia","volume":"Volume 17","author":"Geset Haile","year":"2021","journal-title":"Vasc Health Risk Manag"},{"key":"2026092810003120000_16.9.e123421.27","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302962."},{"key":"2026092810003120000_16.9.e123421.28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1155\/S1463924690000049","article-title":"International Federation of Clinical Chemistry (IFCC): Scientific Division, Committee on Enzymes. IFCC methods for the measurement of catalytic concentration of enzymes. Part 7. IFCC method for creatine kinase (ATP: creatine (N\u2010phosphotransferase, EC 2.7.3.2). IFCC Recommendation","volume":"12","author":"H\u00f8rder","year":"1990","journal-title":"J Anal Methods Chem"},{"key":"2026092810003120000_16.9.e123421.29","unstructured":"American Board of Internal Medicine. ABIM laboratory test reference ranges \u0336 january 2025. American Board of Internal Medicine; 2025.1\u201312."},{"key":"2026092810003120000_16.9.e123421.30","first-page":"1","article-title":"Dysmetabolisms Can Affect Total Antioxidant Capacity (TAC) of Human Plasma: Determination of Reference Intervals of TAC by Way of CUPRAC-BCS Method","volume":"10","author":"Prenesti","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"2026092810003120000_16.9.e123421.31","first-page":"1","article-title":"A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach","volume":"0","author":"Oberts","year":"2011","journal-title":"Aging"},{"key":"2026092810003120000_16.9.e123421.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2014.07.010"},{"key":"2026092810003120000_16.9.e123421.33","doi-asserted-by":"publisher","DOI":"10.1093\/geronj\/49.2.M85"},{"key":"2026092810003120000_16.9.e123421.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.08.011"},{"key":"2026092810003120000_16.9.e123421.35","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/56.3.M146"},{"key":"2026092810003120000_16.9.e123421.36","doi-asserted-by":"crossref","unstructured":"Duarte MP , N\u00f3brega OT , Vogt BP , et al . Prevalence of and factors associated with sarcopenia in patients on hemodialysis in Brazil: findings from the multicenter SARC-HD study. Front Med 2026;12. doi:10.3389\/fmed.2025.1671237","DOI":"10.3389\/fmed.2025.1671237"},{"key":"2026092810003120000_16.9.e123421.37","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/toxins13070472","article-title":"Association of Sarcopenia and Gut Microbiota Composition in Older Patients with Advanced Chronic Kidney Disease, Investigation of the Interactions with Uremic Toxins, Inflammation and Oxidative Stress","volume":"13","author":"Margiotta","year":"2021","journal-title":"Toxins (Basel)"},{"key":"2026092810003120000_16.9.e123421.38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3390\/toxins14040263","article-title":"Methylglyoxal Induces Inflammation, Metabolic Modulation and Oxidative Stress in Myoblast Cells","volume":"14","author":"Todoriki","year":"2022","journal-title":"Toxins (Basel)"},{"key":"2026092810003120000_16.9.e123421.39","doi-asserted-by":"crossref","first-page":"111266","DOI":"10.1016\/j.exger.2021.111266","article-title":"Association between the uremic toxins indoxyl-sulfate and p-cresyl-sulfate with sarcopenia and malnutrition in elderly patients with advanced chronic kidney disease","volume":"147","author":"Caldiroli","year":"2021","journal-title":"Exp Gerontol"},{"key":"2026092810003120000_16.9.e123421.40","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092757"},{"key":"2026092810003120000_16.9.e123421.41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2026.1733798","article-title":"Chronic inflammation as a driving factor for sarcopenia: an update on pathophysiology and future therapeutic targets","volume":"17","author":"Liang","year":"2026","journal-title":"Front Pharmacol"},{"key":"2026092810003120000_16.9.e123421.42","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41430-024-01486-w","article-title":"The association between inflammatory cytokines and sarcopenia-related traits: a bi-directional Mendelian randomization study","volume":"78","author":"Wang","year":"2024","journal-title":"Eur J Clin Nutr"},{"key":"2026092810003120000_16.9.e123421.43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fendo.2022.972238","article-title":"Editorial: The relationship between sarcopenia and metabolic diseases: Its formation mechanism and intervention means","volume":"13","author":"Cheng","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026092810003120000_16.9.e123421.44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20020329"},{"key":"2026092810003120000_16.9.e123421.45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2025.1633837","article-title":"Comparison of sarcopenia screening indices using serum creatinine and cystatin C in metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hwang","year":"2025","journal-title":"Front Med"},{"key":"2026092810003120000_16.9.e123421.46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12944-025-02464-2","article-title":"Relationship of monocyte to high-density lipoprotein ratio (MHR) and other inflammatory biomarkers with sarcopenia: a population-based study","volume":"24","author":"Xue","year":"2025","journal-title":"Lipids Health Dis"},{"key":"2026092810003120000_16.9.e123421.47","doi-asserted-by":"crossref","unstructured":"Kumar R , Prakash SS , Priyadarshi RN , et al . Sarcopenia in Chronic Liver Disease: A Metabolic Perspective. J Clin Transl Hepatol 2022;000. doi:10.14218\/JCTH.2022.00239","DOI":"10.14218\/JCTH.2022.00239"},{"key":"2026092810003120000_16.9.e123421.48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnut.2021.774030","article-title":"Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease","volume":"8","author":"Zambon Azevedo","year":"2022","journal-title":"Front Nutr"},{"key":"2026092810003120000_16.9.e123421.49","doi-asserted-by":"crossref","first-page":"112571","DOI":"10.1016\/j.exger.2024.112571","article-title":"Sarcopenia in cirrhosis: From pathophysiology to interventional therapy","volume":"196","author":"Chen","year":"2024","journal-title":"Exp Gerontol"},{"key":"2026092810003120000_16.9.e123421.50","first-page":"1","article-title":"Association between chronic kidney disease and sarcopenia and emerging treatment strategies","volume":"12","author":"Li","year":"2025","journal-title":"Front Nutr"},{"key":"2026092810003120000_16.9.e123421.51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.17987\/jcsm-cr.v3i1.57","article-title":"Relationship between sarcopenia and the serum creatinine\/cystatin C ratio in Japanese rural community\u2010dwelling older adults","volume":"3","author":"Kusunoki","year":"2018","journal-title":"JCSM Clinical Reports"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-123421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:12Z","timestamp":1790614872000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-123421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-123421"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-123421","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}